US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

SeaStar Medical Holding Corporation

0.0419

-0.0070-14.31%

Volume:35.25K

Turnover:1.64K

Market Cap:- -

PE:- -

High:0.0475

Open:0.0473

Low:0.0400

Close:0.0489

52wk High:0.0730

52wk Low:0.0140

Shares:- -

Float Shares:- -

Volume Ratio:0.75

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:-156.15%

PB:0.00

PE(LYR):- -

Loading ...

Overview Company News Filings

SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time

FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery

Q4 2024 SeaStar Medical Holding Corp Earnings Call

Thomson Reuters StreetEvents

SeaStar Medical Holding Corp (ICU) Q4 2024 Earnings Call Highlights: Strategic Advances Amidst ...

SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025

NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ICUCW/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ICUCW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ICUCW\",,,,,undefined,":{"symbol":"ICUCW","market":"US","secType":"STK","nameCN":"SeaStar Medical Holding Corporation","latestPrice":0.0419,"timestamp":1755540992020,"preClose":0.0489,"halted":0,"volume":35253,"delay":0,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-0.007,"latestTime":"08-18 14:47:05 EDT","open":0.0473,"high":0.0475,"low":0.04,"amount":1639.88072244,"amplitude":0.153374,"askPrice":0.0469,"askSize":1908,"bidPrice":0.0419,"bidSize":17236,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1755547200000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":0.0489,"volumeRatio":0.750383},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ICUCW\",,,,,undefined,":{"symbol":"ICUCW","floatShares":0,"roa":"-156.15%","roe":"--","lyrEps":0,"volumeRatio":0.750383,"shares":0,"dividePrice":0,"high":0.0475,"amplitude":0.153374,"preClose":0.0489,"low":0.04,"week52Low":0.014,"pbRate":"0.00","psRate":"0.00","week52High":0.073,"institutionHeld":0,"latestPrice":0.0419,"committee":0.800669,"eps":0,"divideRate":0,"volume":35253,"delay":0,"ttmEps":0,"open":0.0473,"prevYearClose":0.0206,"prevWeekClose":0.0432,"prevMonthClose":0.0289,"prevQuarterClose":0.0199,"fiveDayClose":0.0449,"twentyDayClose":0.0259,"sixtyDayClose":0.0301},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ICUCW\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ICUCW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ICUCW\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ICUCW\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531031765","title":"SeaStar Medical Announces CEO Interview on Benzinga All Access to Occur Today at Approximately 10:50 am Eastern Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2531031765","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531031765?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:05","pubTimestamp":1746014700,"startTime":"0","endTime":"0","summary":"DENVER, April 30, 2025  -- SeaStar Medical Holding Corporation , a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that Eric Schlorff, CEO of SeaStar Medical, will be a featured guest today, Wednesday, April 30th, at approximately 10:50 am Eastern Time on the Benzinga All Access Show.feature=share. An archived recording of the presentation will be available on the investor relations section of the Sea Star Medical’s website on the Events and Presentations page.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/seastar-medical-announces-ceo-interview-120500310.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ICUCW","SCD","BK4161","ICU","EML"],"gpt_icon":0},{"id":"2525089154","title":"FDA Grants SeaStar Medical Two New Breakthrough Device Designations for SCD Therapy to Treat Systemic Inflammatory Response in Adult and Pediatric Patients Undergoing Cardiac Surgery","url":"https://stock-news.laohu8.com/highlight/detail?id=2525089154","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525089154?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:05","pubTimestamp":1744113900,"startTime":"0","endTime":"0","summary":"DENVER, April 08, 2025  -- SeaStar Medical Holding Corporation , a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that the U.S. Food and Drug Administration  has granted SeaStar Medical two new Breakthrough Device Designations for its Selective Cytopheretic Device  therapy. The two new Breakthrough Device Designations are indicated for the treatment of systemic inflammatory response in 1) adult patients undergoing cardiac surgery and 2) pediatric patients undergoing cardiac surgery towards prevention of post-operative adverse complications and outcomes. Approximately 15 percent of the estimated 300,000 adults that undergo cardiac surgery each year are considered high risk and, we believe, could benefit most from the SCD therapy to prevent post-surgical complications. Of the 40,000 pediatric patients that undergo congenital heart surgery each year, we believe that approxi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-grants-seastar-medical-two-120500036.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ICU","BK4212","ICUCW","BK4585","BK4588","CPB","BK4082","SCD"],"gpt_icon":0},{"id":"2522853578","title":"Q4 2024 SeaStar Medical Holding Corp Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853578","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853578?lang=en_us&edition=fundamental","pubTime":"2025-03-28 19:31","pubTimestamp":1743161518,"startTime":"0","endTime":"0","summary":"Jackie Cosman; Investor Relations; WheelHouse Life Science Advisors. Eric Schlorff; Chief Executive Officer, Director; SeaStar Medical Holding Corp. Tim Varacek; Senior Vice President, Commercial & Business Operations; SeaStar Medical Holding Corp. David Green; Chief Financial Officer; SeaStar Medical Holding Corp. Yeah, thank you, Jackie. And thank you all for joining us today. We are excited to share with you our achievements over the past year, and more importantly, our future plans and our passion for what we are doing here at SeaStar Medical. With the launch of Coelimmune, which Tim will talk about shortly, we have witnessed truly amazing patient outcomes. about how our SCD therapy has saved lives. One example was recently sent for publication by investigators at the University of Michigan, where the patient had a 95 % predicted mortality. And after SCD therapy, they have normal kidney function, resumed chemotherapy, and are at home. We have also witnessed s topping almost certain","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-seastar-medical-holding-113158257.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ICUCW","ICU"],"gpt_icon":0},{"id":"2522447519","title":"SeaStar Medical Holding Corp (ICU) Q4 2024 Earnings Call Highlights: Strategic Advances Amidst ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2522447519","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522447519?lang=en_us&edition=fundamental","pubTime":"2025-03-28 15:04","pubTimestamp":1743145471,"startTime":"0","endTime":"0","summary":"Net Revenue: $134,000 in 2024, reflecting initial product adoption timelines.Cash Position: Ended 2024 with $1.8 million in cash.Capital Raised: Approximately $25 million raised in 2024, with an additional $6 million in February 2025.Debt Reduction: Approximately $6 million of debt extinguished in 2024.Operating Expenses: Increased by approximately $3.6 million in 2024 due to commercial launch and clinical trial enrollment.Net Loss: $24.8 million in 2024, down from $26.2 million in 2023.Clinical Trial Enrollment: 94 out of 200 subjects enrolled in the Neutralized AKI Pivotal Trial.GuruFocus has detected 5 Warning Signs with ICU.For the complete transcript of the earnings call, please refer to the full earnings call transcript.SeaStar Medical Holding Corp  launched Coelimmune, witnessing significant positive patient outcomes, including life-saving interventions.Q: What are the plans for expanding Salesforce capabilities in 2025 for the Coelimmune product?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/seastar-medical-holding-corp-icu-070431032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ICU","ICUCW"],"gpt_icon":0},{"id":"2522085246","title":"SeaStar Medical to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2522085246","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522085246?lang=en_us&edition=fundamental","pubTime":"2025-03-25 05:30","pubTimestamp":1742851800,"startTime":"0","endTime":"0","summary":"DENVER, March 24, 2025  -- SeaStar Medical Holding Corporation , a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its fourth quarter and year-end 2024 financial results after market close on Thursday, March 27, 2025, and host a webcast and conference call to discuss its financial results and business progress.Thursday, March 27, at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast and replay can be foundhere.A replay of the call will be available after 7:30 pm ET and can be accessed as follows:. The call replay number is 1  800-9909 and will be available through April 3, 2025.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/seastar-medical-report-fourth-quarter-213000963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SCD","BK4082","ICUCW","ICU"],"gpt_icon":0},{"id":"2520671537","title":"NKF Honors SeaStar Medical, with 2025 Corporate Innovator Award","url":"https://stock-news.laohu8.com/highlight/detail?id=2520671537","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520671537?lang=en_us&edition=fundamental","pubTime":"2025-03-18 20:45","pubTimestamp":1742301900,"startTime":"0","endTime":"0","summary":"Company recognized for treatment recently approved in the U.S. for pediatric acute kidney injury  due to sepsis.NEW YORK, March 18, 2025 /PRNewswire/ -- SeaStar Medical  has been selected to receive the 2025 Corporate Innovator Award from theNational Kidney Foundation at the 2025 Spring Clinical Meetings in Boston.In February 2024, SeaStar Medical's QUELIMMUNE Selective Cytopheretic Device for Pediatrics  received FDA approval as the first and only therapeutic device for the treatment of pediatric Acute Kidney Injury due to sepsis.\"AKI has devastatingly highly rates of morbidity and mortality, especially in children\" said Kevin Longino, CEO, National Kidney Foundation and a kidney transplant recipient. \"This Corporate Innovator Award recognizes SeaStar Medical's significant contribution to improving the lives of pediatric patients with AKI and we congratulate them on this achievement.\". NKF Spring Clinical MeetingsFor more than 30 years, nephrology healthcare professionals from across ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nkf-honors-seastar-medical-2025-124500762.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nkf-honors-seastar-medical-2025-124500762.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SCD","BK4104","BK4539","ICUCW","KRT","BK4082","ICU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":6,"code":"91000000","status":"200"}]}}